Cite
HARVARD Citation
Chevli, K. et al. (2022). Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial. Journal of urology. 207 (1), pp. 61-69. [Online].